Advanced search
Publication Cover
The European Journal of Contraception & Reproductive Health Care Volume 23, 2018 - Issue 2
Submit an article Journal homepage
10,633
Views
18
CrossRef citations to date
0
Altmetric
Original Research Article

Bleeding patterns for the Liletta® levonorgestrel 52 mg intrauterine system

Courtney A. SchreiberDepartment of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA; View further author information
,
Stephanie B. TealDepartment of Obstetrics and Gynecology, University of Colorado, Aurora, CO, USA; View further author information
,
Paul D. BlumenthalDepartment of Obstetrics and Gynecology, Stanford University, Stanford, CA, USA; View further author information
,
Lisa M. KederDepartment of Obstetrics and Gynecology, Ohio State University, Columbus, OH, USA; View further author information
,
Andrea I. OlariuMedicines360, San Francisco, CA, USA; View further author information
&
Mitchell D. CreininDepartment of Obstetrics and Gynecology, University of California, Sacramento, CA, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0001-5967-8180View further author information
ORCID Icon
Pages 116-120 | Received 21 Aug 2017, Accepted 04 Mar 2018, Published online: 21 Mar 2018

References

  • Belsey EM, Machin D, d’Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 1986;34:253–260.
  • US Food and Drug Administration [Internet]. Washington (DC): Centre for Drug Evaluation and Research. Mirena. FDA drug approval package. Clinical pharmacology biopharmaceutics review(s); [cited 2017 Aug 8]. Availabe from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-225.pdf_Mirena_BioPharmr.pdf
  • Eisenberg DL, Schreiber CA, Turok DK, et al. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. Contraception. 2015;92:10–16.
  • Kyleena. Package insert. Kyleena prescribing information. Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ. 2016.
  • Skyla. Package insert. Skyla prescribing information Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ. 2017.
  • Mishell DR Jr, Guillebaud J, Westhoff C, et al. Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. Contraception. 2007;75:11–15.
  • Liletta package insert: Allergan USA Inc. and Medicines360. Liletta prescribing information, 2016.
  • Mirena. Package insert. Mirena prescribing information. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc. 2017.
  • Nelson A, Apter D, Hauck B, et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial. Obstet Gynecol. 2013;122:1205–1213.
  • Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril. 2012;97:616–622.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.